CN107468696A - A kind of dietary supplements and its preparation method and application - Google Patents
A kind of dietary supplements and its preparation method and application Download PDFInfo
- Publication number
- CN107468696A CN107468696A CN201710588224.2A CN201710588224A CN107468696A CN 107468696 A CN107468696 A CN 107468696A CN 201710588224 A CN201710588224 A CN 201710588224A CN 107468696 A CN107468696 A CN 107468696A
- Authority
- CN
- China
- Prior art keywords
- dietary supplements
- extract
- saturated
- liquor
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims description 24
- 239000000284 extract Substances 0.000 claims abstract description 111
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 claims abstract description 56
- PQDRXUSSKFWCFA-CFNZNRNTSA-N solanone Chemical class CC(=O)CC[C@@H](C(C)C)\C=C\C(C)=C PQDRXUSSKFWCFA-CFNZNRNTSA-N 0.000 claims abstract description 52
- 235000003248 hydroxytyrosol Nutrition 0.000 claims abstract description 44
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims abstract description 35
- 230000036541 health Effects 0.000 claims abstract description 28
- 239000000047 product Substances 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 21
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 17
- 235000005911 diet Nutrition 0.000 claims abstract description 9
- 230000000378 dietary effect Effects 0.000 claims abstract description 5
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 56
- 240000004482 Withania somnifera Species 0.000 claims description 50
- 235000001978 Withania somnifera Nutrition 0.000 claims description 48
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 30
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 230000036542 oxidative stress Effects 0.000 claims description 25
- 229930182877 withaferin Natural products 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- 239000004006 olive oil Substances 0.000 claims description 15
- 235000008390 olive oil Nutrition 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 240000007817 Olea europaea Species 0.000 claims description 12
- 244000061458 Solanum melongena Species 0.000 claims description 11
- 235000002597 Solanum melongena Nutrition 0.000 claims description 11
- 230000003064 anti-oxidating effect Effects 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 230000035882 stress Effects 0.000 claims description 9
- 230000000451 tissue damage Effects 0.000 claims description 9
- 231100000827 tissue damage Toxicity 0.000 claims description 9
- 210000001367 artery Anatomy 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 235000019504 cigarettes Nutrition 0.000 claims description 6
- 230000007958 sleep Effects 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 21
- 150000003254 radicals Chemical class 0.000 description 31
- 206010061218 Inflammation Diseases 0.000 description 30
- 230000000694 effects Effects 0.000 description 30
- 230000004054 inflammatory process Effects 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000011160 research Methods 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000003963 antioxidant agent Substances 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 16
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 239000010408 film Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 238000003915 air pollution Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- -1 radiation Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 150000002596 lactones Chemical class 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 6
- 235000001412 Mediterranean diet Nutrition 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000008184 Piper nigrum Nutrition 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 235000004330 tyrosol Nutrition 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 244000203593 Piper nigrum Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 235000013614 black pepper Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000009405 Ashwagandha Substances 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 241000758706 Piperaceae Species 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000809 air pollutant Substances 0.000 description 3
- 231100001243 air pollutant Toxicity 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000027288 circadian rhythm Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 108010088547 ARNTL Transcription Factors Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101150038243 CLOCK gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 2
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 description 2
- 235000019510 Long pepper Nutrition 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 235000002725 Olea europaea Nutrition 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 240000003455 Piper longum Species 0.000 description 2
- 102100024261 Protocadherin alpha-4 Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000006937 anti-inflammatory bioactivity Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 102000008867 ARNTL Transcription Factors Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010041290 Soft tissue inflammation Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JAVFSUSPBIUPLW-QEWGJZFKSA-N Withanolide Natural products O=C1[C@@H](C)[C@H](C)C[C@H]([C@@H](C)[C@@H]2[C@@]3(C)[C@H]([C@@H]4[C@@H]([C@]5(C)[C@@H](CC4)CCCC5)CC3)CC2)O1 JAVFSUSPBIUPLW-QEWGJZFKSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006944 antioxidant bioactivity Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021197 fiber intake Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000001256 muscle mitochondria Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- SASUFNRGCZMRFD-WVKTXKMSSA-N withanolide Chemical compound C1C(C)=C(C)C(=O)O[C@@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-WVKTXKMSSA-N 0.000 description 1
- FAZIYUIDUNHZRG-PCTWTJKKSA-N withanone Chemical compound C([C@@H]1[C@@H](C)[C@]2(O)[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=CC[C@]5(O)[C@H]5O[C@H]5[C@H]4[C@@H]3CC2)C)C(C)=C(C)C(=O)O1 FAZIYUIDUNHZRG-PCTWTJKKSA-N 0.000 description 1
- FAZIYUIDUNHZRG-BIILLMFASA-N withanone Natural products C[C@H]([C@@H]1CC(=C(C)C(=O)O1)C)[C@@]2(O)CC[C@H]3[C@@H]4[C@@H]5O[C@@H]5[C@@]6(O)CC=CC(=O)[C@]6(C)[C@H]4CC[C@]23C FAZIYUIDUNHZRG-BIILLMFASA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of dietary supplements, count in parts by weight, the dietary supplements includes:40 53 parts of liquor-saturated solanone extracts, 20 27 parts of withaferin A extracts, 10 20 parts of hydroxytyrosols and 10 20 parts of piperings.The dietary supplements of the present invention can further comprise upper dietetic product and/or pharmaceutically acceptable carrier and/or auxiliary material so that peroral dosage form is made.The dietary supplements of the present invention has remarkable anti-inflammatory and antioxidant effect, can be further used for preparing health products and medicine.
Description
Technical field
The invention belongs to medicines and health protection field, in particular it relates to a kind of dietary supplements and preparation method thereof and
Using.
Background technology
Although huge effort has been made in terms of the quality of health care is improved to extend human longevity, to provide
It is more prone to the medical scheme obtained, but the incidence of disease of many serious diseases still persistently raises.These diseases include:Cardiac muscle stalk
Plug (also referred to as heart disease), apoplexy, cancer, diabetes, hypertension, arthritis, obesity, chronic obstructive lung (COPD), its
Its disease relevant with smoking or air pollution and nerve degenerative diseases such as Alzheimer's disease and Parkinson's disease.
The cost and activity of medical research now are unprecedented surging.Such research activities has confirmed many serious diseases
(and causing the principal disease of human death) can be prevented.Such prevention is based on several factors, is related to heredity, drink
Food, habits and customs and environmental factor.
Inflammation and its relation with disease
Today, the common physiologic feature of many most common and serious disease was relevant with the pathology for being referred to as inflammation.Slowly
Property body inflammation be one be used for a series of body chemistries reaction and phenomenon broad terms, its metabolic state to body
There is significant impact with process.
Inflammation is beneficial to human body.For example, excessively receive solar ultraviolet irradiation, can cause erythrosis and tan severely with
Occur.In this case, inflammation excessively receive as body solar ultraviolet irradiation immune response, advantageously reduce by
Acute and chronic damage caused by skin.
Influenza virus infection can cause body temperature to raise, and be referred to as having a fever.Fever is the inflammatory mechanism to protect the health of body,
It is intended to reduce survival ability and the survival of intrusive viruses.Therefore, such inflammation is beneficial to the health of the mankind, and sometimes
It is vital.
When for example hot pan in the surface of skin contact to the heat of the mankind, inflammation also occurs.In this case,
Inflammation makes body produce a series of immunology and Circulatory response, to repair because contact high temperature damages to caused by skin
Evil.Therefore, in several cases, inflammation is helpful to the health of body.
However, the generation and exacerbation of inflammation and specified disease caused by chronic body illness have very big relation.Coronary heart disease,
Cancer, hypertension, diabetes, metabolic syndrome, hypercholesterolemia, arthritis, obesity and Alzheimer disease are demonstrate,proved
It is bright relevant with the chronic abnormal rise of inflammation in vivo.Specific biomarker, particularly C reactive protein (CRP) can be entered
Row is measured to prove these inflammation.
Inflammation is also likely to be that calorie is intensive, the direct result of the excessive food of natural deletions fiber consumption, which increase
The risk of increased weight.Such increased weight can produce the accumulation of stomach fat and interior fat.Unnecessary stomach fat and
The increase of the yield of the inflammatory molecule that is referred to as cell factor of the interior fat with that can enter the circulatory system has very big pass
System.So, they can cause the inflammatory response of body, so as to increase the risk of relevant disease.
A kind of most obvious inflammatory molecule is interleukin-6 (IL-6) caused by stomach fat.In portal vein
High-caliber IL-6 is measured, the vein of wherein portal vein from consumption stomach fat receives blood.In addition, high-caliber IL-6 with
The CRP of high blood level is directly related.The oxidative stress of inflammation-induced can also increase the presence of other detrimental cytokines, these
Detrimental cytokines include transforming growth factor-β (TGF-β) and tumor necrosis factor-alpha (TNF-α).
Disease caused by a kind of common and inflammation that is known is atherosclerosis.Inflammatory cytokine compound can
The integrality of the crucial vascular endothelial cell of body, such as the arteria carotis of the coronary artery of heart and neck can be changed.Subsequent
Inflammatory response promotes abnormal accumulation of the adipocyte in arterial endothelial cell.Such case is referred to as atherosclerosis, such as
Fruit, which is developed as one pleases, may result in blood vessel diameter and significantly reduces.
Fat aggregation in vascular wall is referred to as patch.In some cases, it is complete may to lose its for unstable patch
Whole property, especially in height inflammatory conditions or experience oxidative stress, cause plaque rupture.This phenomenon and the spot from damage
Block is relevant with the blood leakage of final thrombus, and wherein thrombus is clot.The formation of arterial thrombus be cause most heart and
The reason for a variety of apoplexy.
Chronic body inflammation is relevant with fasting blood glucose level rise, while relevant with ferroheme A1c increase.It is overweight and have
The obese individuals of excessive internal organ and stomach fat are nor coincidence, they also can be to the influence of the circulation insulin as caused by pancreas
Resistance is produced, ultimately results in the long-term rise of blood sugar level.This is referred to as diabetes B.
Also easily increase suffers from the risk of malignant tumour to patient with chronic body inflammation.Some most common human carcinomas
Disease, including lung cancer, colorectal cancer, breast cancer, liver cancer, stomach cancer and prostate cancer are easily sent out compared with other healthy individuals
Life is with the chronic increased patient of body level of inflammation.
Individual body phase of the verified patient with stages alzheimer's disease and Parkinson's disease of researcher with being not suffering from these diseases
Than having higher levels of level of inflammation.
Oxidative stress and its relation with disease
In human body, oxidation is the important physiology course of production energy.However, during production energy, oxygen spreads out
Raw free radical is also produced.Sometimes the generation of such free radical is uncontrolled and the histocyte of the mankind may be made
Into a series of injuries.
Under its simplest pattern, when the amount deficiency that excessive free radical or anti-oxidizing compounds be present, or two kinds of feelings
Condition simultaneously in the presence of, the oxidative stress of appearance is potentially to the process of histologic lesion.Caused by unopposed free radical activity
Infringement be classified as oxidative stress.
Under normal physiological conditions, all atoms have paired outer-shell electron, and therefore have to adjacent tissue
There is obvious reactivity.Free radical is defined as, containing single not paired electronics, substantially increasing its tissue reactive.
Under biotic environment, due to these free radicals or compound may not make any distinction between with neighbouring molecule and cell effect, because
The tissue reactive of this this free radical is probably breakneck.
Free radical may produce known " electronic theft " (electron stealing) phenomenon, cause tissue oxidizing
And destination organization molecule may be made to lose activity.If the concentration of free radical is sufficiently large, these reactions are likely to result in extensively
Cellular damage.
According to anti-oxidizing compounds relative bioavailability is neutralized, the degree of tissue damage may relax or reduce.This
Class antioxidant directly and radical reaction, and neutralizes their reactivity, and linked groups' toxicity with low degree.
Oxidative stress may cause oxide-containing chemical material excessive, be referred to as active oxygen (ROS).The drastically rise of ROS concentration
There may be obvious cellular damage.
Oxidative stress may be produced by many reasons, including diet is bad, toxin, radiation, medicine and air pollution.The world
Contain a large amount of pollutants in the surrounding air in upper many areas.There are some even free radicals in itself in these air pollutants,
Such as nitrogen dioxide.The acute and chronic result for contacting these air pollutants is that oxidative stress occurs for lung, once these are dirty
Dye thing, which is drawn through and into the circulatory system, will trigger systemic oxidative stress.
The lung selective oxidation that air pollution triggers stress can then induce larger range of inflammatory reaction, then release in vivo
Put more free radicals.If lack enough antioxidants, it may occur that serious tissue damage.
Especially, DNA in nucleus may be influenceed by being related to the free radical tissue damage of cell tissue nucleic acid.So,
Therefore the cell effect for causing cancer to occur may be caused by being chronically exposed in pollutant.
Particle diameter is less than 10 μm of particle in airborne particulates, especially aerodynamics, because its oxidative stress is anti-
The a large amount of generations and the generation of free radical answered, may be to the healthy particularly hazardous of the mankind.
These airborne particulates can also cause serious tissue damage, and locally and systemically property inflammation, ultimately forms cancer
Cell simultaneously triggers other inflammation related diseases.
In some areas, air pollution has become chief city's residents ' health problem.Particularly, different sizes and group
Into air pollution particle in terms of the ability that they endanger human health particularly their induced oxidations stress ability side
Face plays an important role.Ultrafine particle and other tiny materials less than 0.1 μm can be inhaled into and by internal macrophage
Taken in epithelial cell.This intake easily induces human body oxidative stress.
In addition, oxidative stress can also be significantly greatly increased for other air pollutants such as polycyclic aromatic hydrocarbon (PAH) and final tissue damages
The danger of wound.
Anti-oxidizing compounds such as anthocyanidin and Flavonoid substances have the ability for removing these free radicals, it is meant that they
Eliminate the danger that these free radicals enter human cell.In this case, these nutrient for plants reduce free radical pair
Cell and the infringement prevented.
The neutralization of free radical has a variety of benefits to human body.The benefit includes reducing coronary heart disease, cranial vascular disease, cancer
With other tumour syndromes, diabetes, obesity, nerve degenerative diseases, arthritis and the risk for accelerating tissue aging.
Another common factors for improving interior free yl concentration is muscular training, the especially aerobic exercise of high intensity.
Increased Skeletal Muscle Contraction produces a large amount of excessive free radical compounds.
The generation of this free radicals a large amount of as caused by motion, hinders ability to act of the muscle in optimum level, extends
Recovery period of overexercise, and the danger of muscle damage may be improved, it is referred to as pulled muscle or muscle tear.
The clinical research for performing high intensity interval tranining (HIIT) sportsman is shown, when sportsman take it is oral anti-oxidant
During agent, its energy production and athletic performance are optimal.It has been shown that HIIT its there is the bone that suppression is referred to as human body " energy plants "
The ability of bone Muscle Mitochondria, to eliminate the accumulation of the free radical related to moving.
The content of the invention
Technical problem solved by the invention is to lack in the prior art while have excellent anti-inflammatory and an antioxidation
Dietary supplements.
On the one hand, the invention provides a kind of dietary supplements, count in parts by weight, the dietary supplements includes:40-
53 parts of liquor-saturated solanone extracts, 20-27 part withaferin As extract, 10-20 parts hydroxytyrosol and 10-20 part piperings.
Foregoing dietary supplements, is counted in parts by weight, and the dietary supplements includes:The liquor-saturated solanone extract of 43-51 parts,
21-25 part withaferin As extract, 12-18 parts hydroxytyrosol and 12-18 part piperings.
Foregoing dietary supplements, is counted in parts by weight, the dietary supplements include 47 parts of liquor-saturated solanone extracts, 23 parts
Withaferin A extract, 15 parts of hydroxytyrosols and 15 parts of piperings.
Foregoing dietary supplements, the liquor-saturated solanone extract and withaferin A extract extract from withania somnifera
(Withania somnifera) root, and/or withania somnifera (Withania somnifera) leaf.
Foregoing dietary supplements, the hydroxytyrosol extract from olive fruits, olive oil and/or water extract.
Foregoing dietary supplements, the pipering extract from black pepper.
Foregoing dietary supplements, the dietary supplements further comprise that dietetic product is upper and/or can pharmaceutically connect
The carrier and/or auxiliary material received.
Foregoing dietary supplements, the dietary supplements are made into peroral dosage form;Preferably, the peroral dosage form is scattered
Agent, tablet, capsule, granule, oral liquid or pill.
On the other hand, the invention provides the preparation method of foregoing dietary supplements, the preparation method to include:According to
Predetermined ratio prepares liquor-saturated solanone extract and withaferin A extract, hydroxytyrosol and pipering;And by liquor-saturated solanone extract and
Withaferin A extract, hydroxytyrosol and pipering uniformly mix.
Foregoing preparation method, the liquor-saturated solanone extract and withaferin A extract use supercritical CO2Abstraction technique
And/or moisture film extraction filtering technique, and/or be impregnated and saturated with being prepared.
Foregoing preparation method, the hydroxytyrosol are prepared using moisture film extraction filtering technique.
Foregoing preparation method, the pipering use supercritical CO2Abstraction technique is prepared.
On the other hand, the invention provides foregoing dietary supplements to prepare health products or medicine with antioxidation
Application in product.
On the other hand, the invention provides foregoing dietary supplements to prepare health products or medicine with antiinflammatory action
In application.
On the other hand, the invention provides foregoing dietary supplements prepare prevention and/or treat it is following any one
Or the application in the health products or medicine of a variety of diseases or symptom:Oxidative stress, chronic inflammation, angiocardiopathy (CVD), artery
Hardening, cancer, Arterial Hypertention, diabetes, Health cost caused by hypercholesterolemia and similar relevant disease, cigarette,
Oxidative stress caused by pollution and tissue damage, age-related body aging, overweight and fat, bacterium infection and sleep
Related obstacle, with anxiety and stress be related symptom and situation, nerve degenerative diseases, skin symptom and ultraviolet initiation
Loss.
The beneficial effects of the invention are as follows:The present invention dietary supplements is anti-oxidant and antiphlogistic effects are notable, to it is a variety of with it is scorching
The disease or symptom of disease or oxidative stress correlation have good prevention or therapeutic action.The dietary supplements of the present invention, which has, matches somebody with somebody
Fang Xinying, cost be cheap, evident in efficacy, the advantages that having no toxic side effect, and is applicable to industrialized production.
Embodiment
It is described below being presently contemplated for the best mode embodiment of the present invention.The description is not to be considered as limiting,
It is only used for the purpose of one or more preferred embodiments of the description present invention.Protection scope of the present invention should refer to right
It is required that to determine.
Liquor-saturated solanone (Withanone) and withaferin A (Withaferin A)
Withania somnifera (Withania somnifera) is a kind of popular thousands of years of herbal medicine, for producing traditional remedy
Measure and family's medicine, mainly planted in India and its neighbouring country.It is important that withania somnifera is that Ayurveda (Ayurveda) uses
Medicinal herbs.It is the evergreen shrubs found in India arid area, grows into about 1 meter of height.There is leaf the tree whole year, and is grown in
It is fertile, be sufficiently humidified so as to in well-drained soil.
Ayurveda is initiated by medical system of the India with history in 5000, is often translated into " life science ".
Scientists start to verify the effect of Ayurveda herbal medicine in clinical practice recently.
Withania somnifera has time-honored application in Ayurveda medical science, beneficial to Health and Living custom, including:
(1) immunity,
(2) & memories are learnt,
(3) anti-inflammatory,
(4) assisting sleep, and
(5) stress eliminate.
Withania somnifera is referred to as the renovation agent of Ayurveda medical science.Widely using always for many years, therefore people are
It is extensively study to health promotion, Health restoration and the value for continuing life.
One of most ancient purposes of withania somnifera be as Ayurveda medicinal herbs resist stress influence.Withania somnifera is claimed
Former to adapt to, can tackle user stress as caused by body or mental fatigue.Known withania somnifera has antiinflammatory property, its
Have been used for treatment of arthritis and infectious diseases.
The reactive compound of withania somnifera just becomes more fully apparent recently.Recent research in cell and animal model is
Channel syndrome understands the multifunctional number of mechanisms perhaps of withania somnifera:Anti-inflammatory, anticancer (Widodo N, et al.Selective
killing of cancer cells by leaf extract of Ashwagandha:identification of a
tumor-inhibitory factor and the first molecular insights to its
effect.Clin.Cancer Res.2007Apr 1;13(7):2298-306), anti-diabetic, resisting stress, anti-oxidant, neural
Protection and immunological regulation.(Aalinkeel R, et al. (201O) Genomic Analysis Highlights the Role
of the JAK-STAT Signaling in the Antiproliferative Effeets of Dietary
Flavonoid-‘Ashwagandha’in Prostate Cancer Cells.Evid.Based Complement
Alternat.Med.2010;7:177-187;Shah N, et al.Effect of the alcoholic extract of
Ashwagandha leaves and its components on proliferation, migration, and
differentiation of glioblastoma cells:combinational approach for enhanced
differentiation.Cancer Sci.2009;100:1740-1747;Mayola E, et al.Withaferin A
induces apoptosis in human melanoma cells through generation of reactive
oxygen species and down-regulation of Bcl-2.Apoptosis 2009;16:1014-1027).
Withania somnifera has antioxidant properties.A use of especially important instruction of withania somnifera is neuroprotection, leads to
Cross and remove the free radical in brain to prevent tissue damage.
Free radical is compound, molecule and the atom for losing an outer-shell electron, thus gives their unstable properties.
In order to become more stable, free radical may obtain the electronics lost from the tissue of health and body fluid, therefore, this
Property is harmful to human body.This phenomenon is referred to as " electronic theft ".So, it has been shown that this property of free radical may
Can increase the risk of disease progression, including angiocardiopathy, cancer and other tumours, degeneration and diseases associated with inflammation, diabetes,
Fat, nerve degenerative diseases.
Because the liquor-saturated solanone and withaferin A in withania somnifera are antioxidants, therefore the mechanism for promoting health activity is to increase
Add the generation of internal natural anti-oxidation enzyme, including superoxide dismutase, catalase and glutathione peroxidase
(Bhattacharya SK, Satyan KS, Ghosal S.Antioxidant activity of glycowithanolides
from Withania somnifera.Indian J Exp.Biol.1997Mar;35(3):236-9).By withania somnifera
As prescription medicine to treat the brain diseases of the elderly, and improve cognitive disorder.
The various water-based and alcohol extracting thing of withania somnifera has been used for treating bacterium infection (Owais M (1), Sharad
KS, Shehbaz A, Saleemuddin M.Antibacterial efficacy of Withania somnifera
(ashwagandha)an indigenous medicinal plant against experimental murine
salmonellosis.Phytomedicine.2005;Mar;12(3):229-35).
Having proven to withania somnifera can effectively treatment of arthritis (Begum VH, Sadique J.Long term as antiinflammatory
effect of herbal drug Withania somnifera on adjuvant induced arthritis in
rats.Indian J Exp.Biol.1988Nov;26(11):877-82).
Withania somnifera leaf contains a kind of compound for being referred to as steroidal lactone, particularly liquor-saturated eggplant lactone (withanolide), its
In liquor-saturated solanone and withaferin A be bioactive compound (Kulkarni SK, Dhir A (2008) Withania somnifera:
an Indian ginseng.Prog.Neuropsychopharmacol.Biol.Psychiatry.2008;32:1093-
1105)。
Except its oxidation resistance, liquor-saturated solanone and withaferin A compound has also been asserted the effect with anti-inflammatory.They
It is especially effective to cancer cell, it can all be used as prevention sex-health replenishers to be used to treat and cancer protection.
Hydroxytyrosol (Hydroxytyrosol)
The cardiovascular health benefits of Mediterranean diet, first by de Lorgeril (Circulation.1999;99:779-
Et al. 785) it was described and delivered as scientific discovery in 1999, it was demonstrated that in the patient having a heart attack in the past, ground
Middle extra large diet is to repeating heart attack with the protective effect for being up to 4 years (4 years are the long term follow-up phases most long in the research).
Similar research shows that all other hazards are identical, such as obesity, smoking, inactive and other diet
Bad, because certain reason stays in, the regional people of Mediterranean basin are more healthy than in the other local adults in the world, and the life-span is more
It is long.Mediterranean diet includes abundant fresh daily water fruits and vegetables, full cereal, nut, berry, olive, red wine, moderate
The fish and poultry of intake, the dairy products of low intake, red meat, manufactured meat and candy, and particularly routine uses olive oil,
Particularly Extra Virgin.
Further scientific research clearly illustrates that the main beneficial compound in Mediterranean diet is present in olive, special
It is not in olive oil.Show after carrying out substantial amounts of comparative studies to the olive oil of different cultivars and grade, with original olive oil and
Non-primary olive oil is compared, and higher quality and more refined Extra Virgin are more helpful to health.
Extra Virgin is different from common olive oil and virgin oil due to its excellent polyphenol content.Therefore
Draw a conclusion, most of health benefits come from olive polyphenol in Mediterranean diet.
So far, in terms of anti-oxidant and anti-inflammatory power, maximally effective polyphenol is hydroxyl junket in olive fruit and olive oil
Alcohol.Hydroxytyrosol is that olive oil has the reason for high stability.The parent compound of hydroxytyrosol is oleuropein, and its is main
Found in olive leaf.The reason for it is the toil pungent of olive, and hydroxytyrosol is relatively tasteless.
The widest population studies for assessing Extra Virgin effect are always PREDIMED researchs (Estruch, et
al.N Engl J Med2013;368:1279-1290).This is the large-scale Prevention Research carried out in Spain, is related to
7447 patients for suffering from high blood pressure disease.Research conclusion shows, supplements the Mediterranean of one liter of Extra Virgin weekly
Diet significantly reduces the incidence of disease of angiocardiopathy.
Because monounsaturated fatty acids (MUFA) of the olive oil containing unsoundness, it is initially considered that these healthy greases rise
Positive health discovery is come from, it is relevant with Mediterranean diet.However, when olive oil with other types of plant oil such as to day
When certain herbaceous plants with big flowers oil and the safflower oil unsaturated oleic acid aliphatic acid of list of similar content (also contain) compare, other vegetable oil do not have generation and
The positive health benefits of Mediterranean diet identical.
These find to confirm (Mol Nutr Food Res.2007Oct by P é rez-Jim é nez et al.;51(10):
1199-208).It has recorded the anti-inflammatory of olive oil, anti-oxidant and less thrombosis effect can not contain due only to its MUFA
Amount.
Therefore, Extra Virgin and other types of olive oil are analyzed in detail, analysis shows, it is and normal
Rule are compared with virgin oil, and Extra Virgin contains more phenolic compounds (also referred to as polyphenols), special
It is not more hydroxytyrosols, improves the higher level of health benefits.
The hydroxytyrosol and other polyphenolic substances found in olive and Extra Virgin is in medical science and section
Learn and widely studied and delivered in the periodical literature of the peer review.They clearly show to have human health great
Interests, it is both the basis of prevention, and the adminicle of patient of the treatment with specified disease.
Pipering (Piperine)
Pipering (black pepper piper longum (piper longum) extract) is a kind of bioavilability reinforcing agent.Pipering
One attracting feature is the inhibitory action that it is reacted enzyme drug biotransformation in liver.Pipering strong inhibition liver and intestines
Road aryl hydrocarbon hydroxylase and UDP-glucoronosyl/transferase.
The Bioaugnentation effect of pipering is also attributed to the enhancing of intestinal absorption to a certain extent, and this is that pipering acts on
The result of the ultra microstructure of microvillus on intestinal brush border.
Although current research indicate liquor-saturated solanone extract and withaferin A extract and hydroxytyrosol have anti-inflammatory and
Antioxidant properties, pipering be bioavilability reinforcing agent, still, the present inventor it has unexpectedly been discovered that, when above-mentioned
Anti-inflammatory and antioxidant properties are significantly increased when material is combined according to special ratios.
According to an aspect of the invention, there is provided a kind of dietary supplements, is counted in parts by weight, including:40-53 parts are liquor-saturated
Solanone extract, 20-27 part withaferin As extract, 10-20 parts hydroxytyrosol and 10-20 part piperings;Preferably, the meals
Food replenishers include:The liquor-saturated solanone extract of 43-51 parts, 21-25 part withaferin As extract, 12-18 parts hydroxytyrosol and 12-18
Part pipering;It is highly preferred that the dietary supplements includes:47 parts of liquor-saturated solanone extracts, 23 parts of withaferin A extracts, 15 parts
Hydroxytyrosol and 15 parts of piperings.
The result of study of inventor shows, when liquor-saturated solanone extract, withaferin A extract, hydroxytyrosol and pipering are pressed
When being combined according to aforementioned proportion, synergy can be obtained.Particularly, dietary supplements of the invention is based on these four components
Combination ability, there is provided the pre- anti-cancer and auxiliary treatment and angiocardiopathy of height and the prevention of Other diseases, with drop
Low or the chronic body inflammation of elimination and oxidative stress, and it is internal to reduce by the anti-oxidation characteristics of each of which and combination
Number of free radical and reactive oxygen species material (ROS).These four anti-oxidant and anti-inflammatory components act on the mankind by be combineding with each other
And animal body is further enhanced with preventing the ability of specified disease by pipering, pipering can be sought by increasing intake plant
Support the intestinal absorption of plain compound, and by reduce intake nutrient for plants compound in liver and intestinal wall inside be metabolized and disappear
Remove, to increase the bioavilability of the nutrient for plants compound of its intake.
On the other hand, when being combined as defined herein to these four compositions, pipering and hydroxytyrosol, liquor-saturated eggplant
Ketone and withaferin A bioactivity vegetalization material synergy, the positive healthy beneficial effect of pipering is by more times of amplifications.
These effects include:Anti-inflammatory, anti-oxidant, anti-rotation shifting, antibacterial, anti-mutation and antitumor properties, and antitumaous effect and anti-apoptotic
Effect, these effects are the pipering other properties healthy and beneficial to humans and animals, and have obtained enhancing and further activation.
In addition to playing the function of bioperformance enhancing agent, by suppressing and being quenched free free radical and active oxygen thing
Matter, and by reducing peroxidatic reaction of lipid and actively impact intracellular mercaptan state, antioxidant molecule and antioxidase,
Pipering is also prevented from the related histologic lesion of oxidative stress.
Compared with the other replenishers for being not belonging to the scope of the invention, the anticancer of dietary supplements of the invention, anti-inflammatory and anti-
Oxidation effectiveness is significantly improved, while effect is more longlasting.With only taking liquor-saturated solanone extract, withaferin A extract, hydroxyl junket
Alcohol is compared with any one in pipering, two or three, or, compared with not using the replenishers that the present invention matches, this
Anticancer, anti-inflammatory and the antioxidant effect of the dietary supplements of invention are significantly higher than the independent effect sum of four kinds of components.A kind of system
The method that ground measured and compared the oxidation resistance of food and replenishers is measurement oxygen radical absorbability (ORAC).Hydroxyl junket
The ORAC of alcohol is TE/ grams of 68,576 micromole.The ORAC of withania somnifera (Withania somnifera) extract is 1505 micro-
Mole TE/100 grams.The ORAC of pipering is 34,053 micromole TE/100g.It is expected that each group of total cooperative effect than the present invention
The summation height at least 100-200% divided.
The main component of withania somnifera (Withania somnifera) extract is compound in liquor-saturated eggplant lactone steroidal,
Liquor-saturated solanone and withaferin A.Withania somnifera extract can be from withania somnifera (Withania somnifera) leaf and withania somnifera
(Withania somnifera) root obtains, it is preferable that using supercritical CO2Abstraction technique and/or moisture film extraction filtering technique
And/or it is impregnated and saturated with extracting liquor-saturated solanone extract and withaferin A extract.Both extractive techniques avoid having used ethanol,
Methanol or other any chemical reagents.
Moisture film extraction filtering technique only uses water as solvent, and supercritical CO2Abstraction technique only makes under elevated pressure conditions
With carbon dioxide that is harmless and being perfectly safe.Moisture film extracts filtering technique while avoiding using chemical solvent, obtains most
Total liquor-saturated eggplant lactone bioactivity beneficial compound of high concentration.Water-based liquor-saturated solanone extract and withaferin A extract it is anti-oxidant
Activity extracted than methanol, acetone, ethanol and chloroform solvent respective extract it is active high.Extract is preferred overcritical
CO2Extraction process produces, to obtain optimal anti-inflammatory bioactivity.Therefore, the present invention by moisture film or will be impregnated and saturated with
Liquor-saturated solanone and the withaferin A extract and liquor-saturated solanone and withaferin A supercritical CO that technology obtains2Extract combination, to obtain
Liquor-saturated eggplant lactone anticancer, the anti-oxidant and anti-inflammatory bioactivity of highest level.
In a kind of preferred embodiment, extraction withania somnifera (Withania somnifera) obtains liquor-saturated solanone
The extraction process of extract and withaferin A extract includes following workshop section:
1. the plant material collection stage
Before the extraction stage, first withania somnifera (Withania somnifera) plant of harvest and root timber material are carried out
Screen, clean, sterilize and grind, to produce the biological active component of final products.
The leaf of plant and root are transported into extraction factory first and carry out cleaning and plant part sorting.In order that liquor-saturated eggplant lactone
The yield of compound is maximum, it is necessary to makes whole plant material selection and processing process system.This will need following device:
(1) it is used for the conveyer belt and system for collecting plant material,
(2) disleave and vibratory sieve separation device, to screen a variety of plant positions, and
(3) washing and sorting line, for cleaning and screening vegetable matter.
2. the plant material primary treatment stage
Withania somnifera plant material must be mechanically and chemically handled to make the extraction of bioactive compound most
Bigization.
Mainly extracted using distilled water to avoid using organic solvent.Use isolation technics, particularly film skill
Art, to carry out flooding and purifying process.These technologies include ultrafiltration, filter, dialysis and electrodialysis successively.
Water-soluble active ingredient is extracted in hot water of the temperature for 100 DEG C or less than 100 DEG C, such as liquor-saturated solanone and liquor-saturated eggplant element
A Phytochemistry compounds.By at 70 DEG C -100 DEG C, at preferably 75 DEG C -90 DEG C, most preferably 80 DEG C -90 DEG C heating and 1 DEG C -
30 DEG C, preferably 10 DEG C -30 DEG C, more preferably 20 DEG C -30 DEG C, at most preferably 20 DEG C -25 DEG C cooling carry out the step.
Liquor-saturated solanone and withaferin A Phytochemistry compound can also pass through supercritical CO2Abstraction technique is extracted.
The liquor-saturated solanone of liquor-saturated eggplant lactone and withaferin A bioactivity vegetalization material that can be extracted from withania somnifera can lead to
Membrane filtration extraction is crossed, therefore due to its water-wet behavior, can use and use aqueous medium and CO2Two kinds of technologies, i.e., by
That is heated at 70 DEG C -100 DEG C is impregnated and saturated with, and supercritical CO2Abstraction technique.Using analysis extraction Characterization of The Products come closely
Monitoring optimization extraction.The standard of Such analysis includes:Uniformity, heat endurance, humidity, fragrance, freezing point, electric conductivity, pH and
Gelling ability.
Carefully for the formulation of concern final products to produce various pulvis, tablet, capsule and liquid extract, this is very
Important.
In a word, the liquor-saturated solanone of withania somnifera and withaferin A extraction equipment needed for above-mentioned technique are as follows:
(1) plant and root grinding device, including industrial grinding mills and plant and root cutter;
(2) supercritical fluid CO2Extraction equipment, extracted for hydrophobic plant chemical compound;
(3) solvent extraction system, this is directed to use with for water-soluble substances or the extraction of the water or ethanol of non-water soluble substance
Device;
(4) be used for the system that slightly puies forward, collect and store, by stainless cylinder of steel and copper pipe of reservoir group into;And
(5) system in extraction process needed for bulk liquids transhipment, is made up of pump and pipeline.
3. separation and enriching stage
Crude extract (including the aqueous solution and alcoholic solution) must be carried out by using the isolation technics of filtering and Distallation systm
Refining.Then, obtained fraction is further concentrated by evaporating, to obtain the bioactive substance of higher concentration.
Further improve the concentration of purified extract using membrane technology, the membrane technology is that nanofiltration, counter-infiltration, freezing are dense
Contracting and vacuum evaporation.
The equipment in these stages includes:Membrane filtration system, for collecting the stainless cylinder of steel and reservoir system of liquid among liquid,
For transporting the pump and pipe-line system of liquid, and concentration and drainage equipment:Vacuum, fluid bed and thin film evaporator.
4. refining stage
Then, the liquid fraction of the concentration obtained to separation and concentration process further carries out refining operation, to incite somebody to action
Specific compound (polyphenol and flavonoids) separates with other materials (salt, sugar and protein).This effectively increases bioactivity
The yield and purity of compound.Further, it is necessary to convert liquids to stable formulation such as powder, and therefore need to dry system
System.
Equipment:
(1) chromatographic system, it is equipped with the industrial columns of ion-exchange chromatography;With
(2) drying system:Fluidized bed drying system, spray drying system, freeze-drier
In the dietary supplements of the present invention, the hydroxytyrosol extracts from olive fruits, olive water extract and/or olive
Oil, it is preferred to use moisture film technology (i.e. moisture film extraction filtering technique or water film filtering technology).Using water as unique solvent, keep away
Exempt to use chemical substance, the antioxidation activity of maximum can be realized by water film filtering technology.Membrane filtration technique including the use of ultrafiltration,
Filter, dialysis and electrodialysis.The concentration of purified extract can be carried out in the steps below using membrane technology:Nanofiltration, counter-infiltration, freezing
Concentration and vacuum evaporation.
Pipering is extracted from black pepper using one of several method.Before extraction process is started, it is necessary to use industry
Grinder is first ground to black pepper.
Pipering can be extracted using dichloromethane.Using aqueous cosolvent, it can bring high yield and high selectivity.
The conventional method of another kind be using potassium hydroxide solution solvent-free residue of the processing from black pepper ethanol extract so as to
Remove the insoluble residue washed in resin and warm ethanol.Alkaloid is crystallized during this by cooling.This is directed to use with
Water and ethanol extractor for water-soluble substances.
Due to of a relatively high expense, the high efficiency method being often eliminated is supercritical CO2Extraction, is used only under high pressure
Harmless and overall safety carbon dioxide.This can bring the pipering of high yield.
In addition to the above-mentioned process conditions referred to, those skilled in the art can determine other according to needs of production
Part.
The dietary supplements of the present invention can be prepared by following steps:According to aforementioned proportion prepare liquor-saturated solanone extract,
Withaferin A extract, hydroxytyrosol and pipering, and by liquor-saturated solanone extract, withaferin A extract, hydroxytyrosol and pepper
Alkali uniformly mixes.
The dietary supplements of the present invention can further comprise that dietetic product is upper and/or pharmaceutically acceptable carrier with/
Or auxiliary material, for example, filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavouring, preservative etc..Filler
Including:Starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc..Disintegrant includes:Carboxymethyl forms sediment
Powder sodium, PVPP, low-substituted hydroxypropyl cellulose, Ac-Di-Sol etc..Lubricant includes:It is stearic
Sour magnesium, lauryl sodium sulfate, talcum powder, silica etc..Suspending agent includes:Polyvinylpyrrolidone, microcrystalline cellulose, sugarcane
Sugar, agar, hydroxypropyl methyl cellulose etc., adhesive includes, starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose
Deng.Sweetener includes:Saccharin sodium, aspartame, sucrose, honey element, enoxolone etc..Flavouring includes:Sweetener and various
Essence, preservative include:Parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, chlorhexidine acetate,
Eucalyptus oil etc..By adding corresponding carrier and/or auxiliary material, oral agents can be further made in dietary supplements of the invention
Type, for example, powder, tablet, capsule, granule, oral liquid or pill etc..In actual production, those skilled in the art can
The dosage of carrier and auxiliary material is determined according to being actually needed, to reach optimal using effect.
When preparing final dietary supplement product, it is necessary to which the production system of such as tablet and capsule, what is be related to is specific
Equipment is to prepare capsule and the powder compressibility needed for tablet.In addition, when preparing final dietary supplement product, also relate to
And packing stage, i.e., final products are packed with solid dosage forms or liquid dosage form, be primarily related to be used for encapsulating products
Blister packaging equipment and bottling line for fluid product.
According to another aspect of the present invention, it is turned into the invention provides foregoing dietary supplements in preparation with antioxygen
Application in health products or medicine.
According to another aspect of the present invention, there is antiinflammatory action in preparation the invention provides foregoing dietary supplements
Health products or medicine in application.
According to another aspect of the present invention, the invention provides foregoing dietary supplements to prepare prevention and/or control
Treat the application in the health products or medicine of any one or more following disease:Oxidative stress, chronic inflammation, angiocardiopathy
(CVD), artery sclerosis, cancer, Arterial Hypertention, diabetes, caused by hypercholesterolemia and similar relevant disease, cigarette
Oxidative stress and tissue damage, age-related body aging, overweight and fat, bacterium sense caused by Health cost, pollution
Dye, the obstacle related to sleep, with anxiety and stress be related symptom and situation, nerve degenerative diseases, skin symptom and
The loss that ultraviolet triggers.
Specifically, dietary supplements of the invention has significant prevention and/or therapeutic effect to following disease or symptom:
1. angiocardiopathy, for example, apoplexy, myocardial infarction and artery sclerosis.The dietary supplements of the present invention passes through reduction
Inflammation reduces the risk of angiocardiopathy with anti-oxidant feature is improved, and can reduce the ability that blood forms thrombus grumeleuse, from
And reduce the ability of their blocked coronary arteries and arteria carotis inner chamber.
2. cancer, such as breast cancer, colon cancer, prostate cancer, cancer of pancreas, lung cancer, and some other tumours.This hair
Bright dietary supplements can suppress growth of cancer cells or directly kill cancer cell, and effectively suppress cancer blood circulation.In addition, this
The chemical signal of generation blood vessel of the dietary supplements of invention to being sent by cancer cell, which has, directly suppresses anti-angiogenesis work
With so as to which the survival rate for the cancer cell for causing to contact with dietary supplements of the invention reduces.
The research of inventor also has confirmed another mechanism of pre- anti-cancer, and it is based on passing through CNR1 promoters site
The change of DNA methylation carrys out transient state up-regulation CNR1 tumor suppressor genes.
3. diabetes.According to the research of inventor, the diabetic for periodically taking the dietary supplements of the present invention, display
Its fasting blood glucose level and the horizontal reduction of glycated hemoglobin (HbA1c).These results show the dietary supplements of the present invention to sugar
Urine patient has positive effect.
HbA1c is the subgroup for circulating red blood cell (red blood cell), and in diabetes and pre-diabetic, its content is higher than
Normal range (NR) (4-5.6%), this is attributed to the corpuscular hemoglobin irreversible glycosylation in β chain N- ends.Scope is 5.7-6.4%
HbA1c high value it is consistent with pre-diabetes condition, so as to add the risk for suffering from diabetes.6.5% or higher water
It is flat consistent with the diagnosis to diabetes.The dietary supplements of the present invention can reduce diabetes and pre-diabetic's
HbA1c is horizontal.
4. cholesterol, particularly serum cholesterol.The dietary supplements of the present invention is to reducing serum low-density LP
(LDL-C) has remarkable effect.
In addition, the dietary supplements of the present invention can cause the aobvious of the serum-concentration of OxLDL ELISA (ox-LDL)
Work reduction and referred to as the inflammation blood plasma biomarker of plasma C-reactive protein (CRP) significantly reduce.LDL-C pairs of oxidation
The harm of cardiovascular health is bigger, because the LDL-C of oxidation produces artery, (particularly heart and arteria carotis is coronal dynamic
Arteries and veins) fat lesion atherosclerotic plaque ability it is stronger.
In addition, the dietary supplements of the present invention can increase the serum levels of HDL (HDL cholesterol), this
It is beneficial in terms of reducing the health risk for suffering from artery sclerosis.The research of inventor also shows that the dietary supplements of the present invention improves
HDL cholesterol efflux abilities, this can improve the healthy curve of user by improving the physiological function of body, so as to clear
The artery that reason has been influenceed by atherosclerosis.
5. hypertension.According to the research of inventor, dietary supplements of the invention significantly reduces systolic pressure and diastolic pressure.
Inventor also found that dietary supplements of the invention is significant to reduce blood pressure and improve the year with mild hypertension
The endothelial function of light women.Due to, it is known that the function of arterial wall endothelial cell plays an important role in hyperpietic is treated, because
This endothelial function is extremely important in the elevated patient of blood pressure.Inner skin cell function is better, and blood pressure is more normal.
6. extend the life-span.Zoopery shows, periodically takes in the longevity of the adult mice of the dietary supplements of the present invention daily
The life-span of the control group adult mice of dietary supplements of the life than not taking in the present invention is extended.The combination enumerated herein
Positive health effect expection the effect in similar extension life-span can be produced to people.
The research of inventor is it is also shown that the dietary supplements of the present invention can slow down cell ageing by some physiological phenomenons
Process.The dietary supplements of the present invention can energetically resist epigenetics (such as DNA methylation) change, telomere is cut down.
The dietary supplements of the present invention can also prevent mitochondria dysfunction and stem cell is exhausted and cell ageing.The meals of the present invention
Food replenishers can prevent the oxidative damage to inhereditary material, so as to promote genome stable.
7. smoking.It is well known that one of harmful mechanism of harmfulness of smoking health is drawn with main and secondary smoking
The body inflammation-related risen.This inflammation causes various disease-angiocardiopathies and cancer to be most common two kinds.
Daily ingestion of dietary supplements of the invention helps to protect human body from harm of smoking.Its mechanism of action is:
1) prevents oxidative stress caused by smoke from cigarette, 2) prevents the damage of lung's antioxidase and increased lipid caused by nicotine
Peroxidation, 3) prevents the inflammation damnification directly contacted between smoke from cigarette and bronchial wall tissue, 4) prevents nicotine
Angiogenesispromoting effect, suppress the growth of tumour and cancer.
8. air pollution.Similar to smoke from cigarette, air pollution can cause oxidative stress, reduce body antioxidase, and
And it is proinflammatory disease.The dietary supplements of the present invention can protect the body from free radical and aoxidize to answer because of its anti-oxidation characteristics
Swash.This protection is then also possible to prevent the sequelae of oxidative stress and air pollution, such as COPD and cancer.
9. skin protection.Skin health is harmful to exposed to ultraviolet radiation.Ultraviolet can damage the bottom branch of skin
Frame albumen (being referred to as collagen and elastin laminin) suppresses skin corium fibroblast metabolism and produces collagen and elastic egg
In vain, and generation also causes dermal tissue insult free radical.
The dietary supplements of the present invention helps to protect skin by eliminating skin free radical, so as to limit the group of correlation
Knit damage.In addition, the dietary supplements of the present invention also enhances the generation of glutathione, this also contributes to protect the skin from certainly
By the injury of base.
The dietary supplements of the present invention has direct inhibitory action to cancer cell, so as to contribute to the skin of protection exposure
From the cutaneum carcinoma of UV inductions, such as the invasion and attack of melanoma.
10. arthritis.Arthritis be it is a kind of influence body joints inflammatory disease, including backbone, buttocks, knee, shoulder,
Ancon, ankle, wrist, pin and pin.Soft tissue inflammation and cartilage inflammation of the dietary supplements of the present invention to arthritis and correlation
With direct effect.
11. body weight.According to the research of inventor, dietary supplements of the invention can lose weight increase, so as to
Prevention or treatment are fat.
12. skin-whitening.The dietary supplements of the present invention can reduce the activity of melanocyte and increase human body paddy Guang
The generation of sweet peptide, so as to bright color.
13. mental health.The dietary supplements of the present invention is by promoting elimination intracerebral amyloid-beta to provide god
Through protection, so as to the prevention and treatment for nerve degenerative diseases such as alzheimer disease (AD) etc..Present invention may also apply to
Improve mental alertness and strengthen cognitive activities.
14. infection.Experiment in vitro proves that dietary supplements of the invention has the property of antibacterial, therefore the meals of the present invention
Eating replenishers can be as the antiseptic applied to prevention enteron aisle and respiratory tract infection.
15. gene clock (Gene Clock).Bioactive substance can in some levels (transcription, RNA it is ripe and steady
Determine, translate into protein and posttranslational modification) influence gene expression.Transcript profile occurs on individual cell level and and organism
Distinctive genome is completely different.According to the research of inventor, have been reported that now clock Physiological effect gene (CLOCK,
Circadian Locomotor Output Cycles Kaput) ratios that methylate of CLOCK CpGs 1 and 8 show, are single
Unrighted acid (MUFA) (Milagro, F.I.et relevant with the intake of aldehydes matter with polyunsaturated fatty acid (PUFA)
Al.Clock, PER2and BMAL1 DNA methylation:Association with obesity and metabolic
Syndrome characteristics and monounsaturated fat intake.Chronobiol.Int.2012,
29,1180-1194.).The hydroxytyrosol component of the present invention has positive role for up-regulation Clock and BMAL1 gene activities.
CLOCK genes are substantially responsible for biological clock rhythm and pace of moving things system, and the system instructs 24- circadian rhythm 24s on gene level.Should
Gene is related to fat and metabolic syndrome.Researcher has been found that patient with visceratonia abdominal fat obesity and suffered from
The patient of metabolic syndrome shows the symptom (timer interrupt) of circadian rhythm disorders, and the illness can produce larger body weight and increase
It is subject to and then fat tendency, further development can causes diabetes and atherosclerosis (G ó mez-Santos, C.et
Al.Circadian rhythm of clock genes in human adipose explants.Obesity 2009,17,
1481-1485).The dietary supplements of the present invention can regulate and control CLOCK gene activation approach, so as to help to prevent and reduction is made
Factor in terms of fat and metabolic syndrome gene.
Causality (Yoshino J, Klein S.A is also likely to be present between the suppression of CLOCK genes and diabetes B
Novel Link Between Circadian Clocks and Adipose Tissue Energy
Metabolism.Diabetes Jul 2009.62(7):2175-7).Therefore, the regulation and control to CLOCK genes contribute to prevention or
Reduce the seriousness of diabetes B.
The research of inventor displays that the epigenetic variation of CLOCK genes is relevant with breast cancer incidence raising, and this is
Because the reduction that methylates of the CLOCK promoter regions of the women to suffer from breast cancer.The dietary supplements of the present invention being capable of actively impact
These are mutated and reduce their influences to CLOCK genes, so as to reduce the risk to suffer from breast cancer.
The research of inventor displays that, causes have height between the somatic mutation of colorectal cancer and CLOCK mutation
Correlation.The dietary supplements of the present invention helps to stablize CLOCK genes to prevent CLOCK mutation, pre- so as to contribute to
CLOCK is mutated in the anti-microsatellite instability target gene for causing colorectal cancer.
Effect of the dietary supplements of the present invention on CLOCK gene expressions can also influence circadian rhythm period, thus regulate and control
Sleep pattern.CLOCK and CYCLE albumen (circulating protein) (dBMAL genes) can form dimer, the compound finally with
Period (gene of per, Per 1) and timeless (tim genes) promoter combine so as to raise (stimulations) per genes with
Tim genes.Therefore, dietary supplements of the invention is the adjusting control agent of CLOCK genes.The regulation activity, which can treat and prevent, sleeps
Dormancy rhythm disorder, and can treat and prevent in the associated disorders caused by the travelling of multiple time zones, the i.e. time difference.
16. take exercise and move.Free radical (FR), also referred to as active oxygen and nitrogen material (RONS), one as eubolism
Part constantly produces (Bentley, et al.Acute and Chronic Effects of Antioxidant in human body
Supplementation on Exercise Performance.Lamprecht M, editor.Antioxidants in
Sport Nutrition.Boca Raton(FL):CRC Press/Taylor&Francis;2015);(Finaud J, Lac
G, Filaire E.Oxidative stress.Sports Medicine.2006;36:327-358).
The FR/RONS of high concentration is harmful to human body, can be caused to the cyto-architectural tight of lipid, protein and DNA
Re-oxidation destroys (Halliwell B, Gutteridge J MC.Free Radicals in Biology and
Medicine.Oxford:Oxford University Press;1999).
Admittedly, daily exercise and high intensity physical training, including high intensity interval tranining (HIIT), can cause it is a large amount of from
By the generation of base.Balance between obtainable antioxidant and oxidant, which has confirmed, can influence contraction of muscle, muscle strength
Produce and energy exports (Clarkson P.M, Thompson H.S.Antioxidants:What role do they play
in physical activity and healthThe American Journal of Clinical
Nutrition.2000;72:637s-646s.).
To the clinical research confirmation that the sportsman for carrying out high intensity interval tranining (HIIt) exercise is carried out when sportsman takes
Ability during oral antioxidant produces and exercise behaves oneself best (Lafay S, Jan C, Nardon K.et al.Grape
extract improves antioxidant status and physical performance in elite male
athletes.Journal of Sports Science and Medicine.2009;8:468-480.);(Shafat A,
Butler P, Jensen R.L, Donnelly A.E.Effects of dietary supplementation with
vitamins C and E on muscle function during and after eccentric contractions
in humans.European Journal of Applied Physiology.2004;93:196-202.).
HIIT has shown that the ability for the skeletal muscle mitochondrial for suppressing to be referred to as human body " energy plants " to remove and to take exercise
Accumulation caused by relevant free radical.
The dietary supplements of the present invention makes muscle performance and strength and energy export and maximize, by the oxygen of musculature
The property changed damage is reduced and minimized it, also, maximizes energy production during intake before exercise.By avoiding mitochondria
Damage and FR/RONS outputs reduce, and dietary supplements of the invention can also strengthen muscle recovery after exercise.
Embodiment
Following examples are only used for describing embodiment of the present invention, and the scope of the present invention should not be restricted by embodiment
Limitation.
Embodiment 1
The composition of the dietary supplements of embodiment 1 is the liquor-saturated solanone extracts of 47mg, 23mg withaferin As extract, 15mg hydroxyls
Base tyrosol and 15mg piperings.
Preparation method:
The liquor-saturated solanone extracts of 47mg, 23mg withaferin As extract, 15mg hydroxytyrosols and 15mg piperings are mixed equal
It is even, produce the dietary supplements of embodiment 1.
Embodiment 2
The composition of the dietary supplements of embodiment 2 is the liquor-saturated solanone extracts of 40mg, 20mg withaferin As extract, 20mg hydroxyls
Base tyrosol and 20mg piperings.
Preparation method:
The liquor-saturated solanone extracts of 40mg, 20mg withaferin As extract, 20mg hydroxytyrosols and 20mg piperings are mixed equal
It is even, produce the dietary supplements of embodiment 2.
Embodiment 3
The composition of the dietary supplements of embodiment 3 is the liquor-saturated solanone extracts of 53mg, 27mg withaferin As extract, 10mg hydroxyls
Base tyrosol and 10mg piperings.
Preparation method:
The liquor-saturated solanone extracts of 53mg, 27mg withaferin As extract, 10mg hydroxytyrosols and 10mg piperings are mixed equal
It is even, produce the dietary supplements of embodiment 3.
Embodiment 4
The composition of the dietary supplements of embodiment 4 is the liquor-saturated solanone extracts of 43mg, 22mg withaferin As extract, 18mg hydroxyls
Base tyrosol and 17mg piperings.
Preparation method:
The liquor-saturated solanone extracts of 43mg, 22mg withaferin As extract, 18mg hydroxytyrosols and 17mg piperings are mixed equal
It is even, produce the dietary supplements of embodiment 4.
Embodiment 5
The composition of the dietary supplements of embodiment 5 is the liquor-saturated solanone extracts of 50mg, 25mg withaferin As extract, 12mg hydroxyls
Base tyrosol and 13mg piperings.
Preparation method:
The liquor-saturated solanone extracts of 50mg, 25mg withaferin As extract, 12mg hydroxytyrosols and 13mg piperings are mixed equal
It is even, produce the dietary supplements of embodiment 5.
Embodiment 6
The composition of the dietary supplements of embodiment 6 is the liquor-saturated solanone extracts of 50mg, 25mg withaferin As extract, 17mg hydroxyls
Base tyrosol and 18mg piperings.
Preparation method:
The liquor-saturated solanone extracts of 50mg, 25mg withaferin As extract, 17mg hydroxytyrosols and 18mg piperings are mixed equal
It is even, produce the dietary supplements of embodiment 6.
Embodiment 7:Oral liquid
The dietary supplement product of embodiment 7 is oral liquid, and the capacity of every oral liquid is 15ml, including:The liquor-saturated eggplants of 47mg
Ketone extract, 23mg withaferin As extract, 15mg hydroxytyrosols, 15mg piperings, sucrose 20mg and water 15ml.
Preparation method:By the liquor-saturated solanone extracts of 47mg, 23mg withaferin As extract, 15mg hydroxytyrosols, 15mg peppers
Alkali, sucrose 20mg are dissolved in 15ml water, well mixed to obtain mixture;Then the mixture is carried out at homogeneous in homogenizer
Reason;Then carry out filling, produce the oral liquid of embodiment 7.
Embodiment 8:Oral liquid
The dietary supplement product of embodiment 8 is oral liquid, and the capacity of every oral liquid is 10ml, including:The liquor-saturated eggplants of 47mg
Ketone extract, 23mg withaferin As extract, 20mg hydroxytyrosols, 10mg piperings, sucrose 20mg and water 10ml.
Preparation method:By the liquor-saturated solanone extracts of 47mg, 23mg withaferin As extract, 20mg hydroxytyrosols, 10mg peppers
Alkali, sucrose 20mg are dissolved in 10ml water, well mixed to obtain mixture;Then the mixture is carried out at homogeneous in homogenizer
Reason;Then carry out filling, produce the oral liquid of embodiment 8.
Embodiment 9:Oral liquid
The dietary supplement product of embodiment 9 is oral liquid, and the capacity of every oral liquid is 5ml, including:The liquor-saturated solanones of 50mg
Extract, 25mg withaferin As extract, 15mg hydroxytyrosols, 10mg piperings, sucrose 20mg and water 3ml.
Preparation method:By the liquor-saturated solanone extracts of 50mg, 25mg withaferin As extract, 15mg hydroxytyrosols, 10mg peppers
Alkali, sucrose 20mg are dissolved in 3ml water, well mixed to obtain mixture;Then the mixture is carried out at homogeneous in homogenizer
Reason;Then carry out filling, produce the oral liquid of embodiment 9.
This document describes the preferred embodiments of the invention, including the optimal side known for inventor for being used to implement the present invention
Formula.After description above is read, the change of these preferred embodiments will become aobvious and easy for those skilled in the art
See.It is expected that this change, and the side that the present invention can be to specifically describe herein can be suitably used in those skilled in the art
Formula is implemented.Therefore, many embodiments of the invention include the institute of theme described in the appended claims that applicable law allows
There are modification and equivalent.In addition, unless otherwise indicated herein or more hereafter clear and definite contradiction, otherwise present invention encompasses it is all can
Any combinations for the above-mentioned key element that can change.
Claims (15)
1. a kind of dietary supplements, it is characterised in that count in parts by weight, the dietary supplements includes:The liquor-saturated solanone of 40-53 parts
Extract, 20-27 part withaferin As extract, 10-20 parts hydroxytyrosol and 10-20 part piperings.
2. dietary supplements according to claim 1, it is characterised in that count in parts by weight, the dietary supplements bag
Include:The liquor-saturated solanone extract of 43-51 parts, 21-25 part withaferin As extract, 12-18 parts hydroxytyrosol and 12-18 part piperings.
3. dietary supplements according to claim 1 or 2, it is characterised in that count in parts by weight, the dietary supplements
Including 47 parts of liquor-saturated solanone extracts, 23 parts of withaferin A extracts, 15 parts of hydroxytyrosols and 15 parts of piperings.
4. according to the dietary supplements described in claim any one of 1-3, it is characterised in that the liquor-saturated solanone extract and liquor-saturated eggplant
Plain A extracts extract from withania somnifera (Withania somnifera) root, and/or withania somnifera (Withania
Somnifera) leaf.
5. according to the dietary supplements described in claim any one of 1-4, it is characterised in that the hydroxytyrosol extracts from olive
Fruit, olive oil and/or water extract.
6. according to the dietary supplements described in claim any one of 1-5, it is characterised in that the pipering extracts from black Hu
Green pepper.
7. according to the dietary supplements described in claim any one of 1-6, it is characterised in that the dietary supplements further wraps
Include that dietetic product is upper and/or pharmaceutically acceptable carrier and/or auxiliary material.
8. according to the dietary supplements described in claim any one of 1-7, it is characterised in that the dietary supplements is made into mouth
Oral dosage form;Preferably, the peroral dosage form is powder, tablet, capsule, granule, oral liquid or pill.
9. the preparation method of the dietary supplements described in claim any one of 1-8, it is characterised in that the preparation method bag
Include:Prepare liquor-saturated solanone extract and withaferin A extract, hydroxytyrosol and pipering according to predetermined ratio;And by liquor-saturated solanone
Extract and withaferin A extract, hydroxytyrosol and pipering uniformly mix.
10. preparation method according to claim 9, it is characterised in that the liquor-saturated solanone extract and withaferin A extract
Using supercritical CO2Abstraction technique and/or moisture film extraction filtering technique, and/or be impregnated and saturated with being prepared.
11. the preparation method according to claim 9 or 10, it is characterised in that the hydroxytyrosol was extracted using moisture film
Filter technology is prepared.
12. according to the preparation method described in claim any one of 9-11, it is characterised in that the pipering uses supercritical CO2
Abstraction technique is prepared.
13. the dietary supplements described in claim any one of 1-8 is in health products or medicine with antioxidation are prepared
Application.
14. the dietary supplements described in claim any one of 1-8 is in health products or medicine with antiinflammatory action are prepared
Using.
15. dietary supplements described in claim any one of 1-8 prepare prevention and/or treat it is following any one or more
Application in the health products or medicine of disease or symptom:Oxidative stress, chronic inflammation, angiocardiopathy (CVD), artery sclerosis,
Cancer, Arterial Hypertention, diabetes, Health cost, pollution are drawn caused by hypercholesterolemia and similar relevant disease, cigarette
It is the oxidative stress risen and tissue damage, age-related body aging, overweight and fat, bacterium infection, related to sleep
Obstacle, to anxiety and stress be related symptom and situation, the damage that triggers of nerve degenerative diseases, skin symptom and ultraviolet
Lose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710588224.2A CN107468696A (en) | 2017-07-18 | 2017-07-18 | A kind of dietary supplements and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710588224.2A CN107468696A (en) | 2017-07-18 | 2017-07-18 | A kind of dietary supplements and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107468696A true CN107468696A (en) | 2017-12-15 |
Family
ID=60595089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710588224.2A Pending CN107468696A (en) | 2017-07-18 | 2017-07-18 | A kind of dietary supplements and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107468696A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690537A (en) * | 2013-12-17 | 2014-04-02 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Novel medicinal application of piperine |
-
2017
- 2017-07-18 CN CN201710588224.2A patent/CN107468696A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690537A (en) * | 2013-12-17 | 2014-04-02 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Novel medicinal application of piperine |
Non-Patent Citations (2)
Title |
---|
KIRTI VAISHNAVI等: "Differential Activities of the Two Closely Related Withanolides, Withaferin A and Withanone: Bioinformatics and Experimental Evidences", 《PLOS ONE》 * |
张书新等: "羟基酪醇的研究进展", 《中国卫生产业》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7897182B2 (en) | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease | |
US8741362B2 (en) | Phytocomplex from bergamot fruit, process of manufacture and use as dietary supplement and in the pharmaceutical field | |
JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
JPWO2006014028A1 (en) | Sweet potato stem and leaf extract and use thereof | |
CN102872306B (en) | Compound selenium Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
JP2010209051A (en) | Fat absorption inhibitor | |
JP6803892B2 (en) | VCAM-1 expression inhibitor | |
JP7007663B2 (en) | Kuro-moji extract | |
Prakash et al. | Therapeutic potential of quercetin and its derivatives in epilepsy: evidence from preclinical studies | |
Halaby et al. | Protective and curative effect of garden cress seeds on acute renal failure in male albino rats | |
KR102337965B1 (en) | Composition for Anti-inflammation Using an Extract of Lemon Peel and a Root Extract of Sophora flavescens | |
CN107456505A (en) | A kind of dietary supplements and its preparation method and application | |
JP2018506524A (en) | Composition for prevention, amelioration or treatment of burnout syndrome | |
RU2162702C1 (en) | Preparation of restorative and tonic action | |
KR101379111B1 (en) | Pharmaceutical composition for preventing or treating inflammatory bowel disease | |
KR101152479B1 (en) | Composition comprising defatted green tea seed extract for preventing and treating inflammatory or cancer disease | |
CN107456504A (en) | A kind of dietary supplements and its preparation method and application | |
CN107468696A (en) | A kind of dietary supplements and its preparation method and application | |
KR102076176B1 (en) | Composition for Anti-inflammation Using an Ginsenoside compound K and an Extract of Lonicera japonica | |
CN107441109A (en) | A kind of dietary supplements and its preparation method and application | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR20120111125A (en) | Composition for treatment of renal cell carcinoma and functional food comprising extract of cannabis semen | |
CN107456470A (en) | A kind of dietary supplements and its preparation method and application | |
CN107349232A (en) | Nutritious supplementary pharmaceutical and its preparation method and application | |
CN107518399A (en) | A kind of dietary supplements and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171215 |
|
RJ01 | Rejection of invention patent application after publication |